Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
264
datasets available to search
ShareScore release 0.9.0
Dataset results
264 results for “virology”
Pilot Project of Virologic and Immunologic Correlates of GALT Immune Reconstitution Following Raltegravir Therapy
ClinicalTrials.gov study NCT00661960. IPD Sharing: Not stated. Countries: 1. Publications: 2.
Study to Evaluate the Efficacy, Safety, and Tolerability of Long-acting Intramuscular Cabotegravir and Rilpivirine for Maintenance of Virologic Suppression Following Switch From an Integrase Inhibitor
ClinicalTrials.gov study NCT02938520. IPD Sharing: YES. Countries: 11. Publications: 12.
Study to Evaluate Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Fixed Dose Combination (FDC) in Virologically-Suppressed HIV-1 Infected Adults Harboring the Arch
ClinicalTrials.gov study NCT02616029. IPD Sharing: YES. Countries: 5. Publications: 1.
Enhanced Virologic Monitoring for Pregnant and Postpartum Women With HIV
ClinicalTrials.gov study NCT05845619. IPD Sharing: NO. Countries: 1. Publications: 1.
Study Evaluating the Safety and Efficacy of Islatravir in Combination With Lenacapavir in Virologically Suppressed People With HIV
ClinicalTrials.gov study NCT05052996. IPD Sharing: NO. Countries: 1. Publications: 1.
A Pilot Project of Virologic, Pharmacologic and Immunologic Correlates of Gastrointestinal-Associated Lymphoid Tissue Immune Reconstitution Following Maraviroc Therapy
ClinicalTrials.gov study NCT00870363. IPD Sharing: Not stated. Countries: 1. Publications: 4.
Switching From a Tenofovir Disoproxil Fumarate (TDF) Containing Regimen to Elvitegravir/Cobicistat/Emtricitabine/ Tenofovir Alafenamide (E/C/F/TAF) Fixed-Dose Combination (FDC) in Virologically-Suppre
ClinicalTrials.gov study NCT02616783. IPD Sharing: YES. Countries: 5. Publications: 1.
Data for "Clinical and virological impact of single and dual infections with influenza A (H1N1) and SARS-CoV-2 in adult inpatients"
<p>The baseline enrolled 505 patients admitted to Guangzhou Eighth People's Hospital (Guangzhou, Guangdong) with a diagnosis of COVID-19 or H1N1. All the patients were tested by both viruses at admission. Demographic, clinical, treatment, and laboratory data were extracted from electronic medical records and compared among adults (≥18 years) hospitalized for H1N1 infection (<em>n</em> = 220), SARS-CoV-2 infection (<em>n</em> = 249) and co-infection with both viruses (<em>n</em> = 36). The prevalence rate of H1N1 co-infection was 12.6% (36/285) among patients hospitalized with COVID-19. Co-infection affected a predominantly older age group and was associated with poorer clinical outcome. We also described the viral load trajectory in patients with diverse types of infection. Lower initial Ct values (higher viral loads in nasopharyngeal swabs) of co-infected patients was found to be associated with a higher number of adverse events and clinical symptoms. Considering the COVID-19 pandemic and a simultaneous epidemic of seasonal influenza, the data in China may critically inform future therapeutic or prophylactic strategies, especially for other developing countries.</p>
HIV-1 Subtypes of HIV-1 patients with virologic failure in different voluntary counseling testing and treatment centers in Khartoum State, Sudan, 2020
<p><strong>Background</strong>: Various HIV subtypes have evolved and play significant roles in the pathogenesis, progression, and response to treating human immunodeficiency virus.</p> <p><strong>Method</strong>: One hundred and ten HIV-1 patients who attended different voluntary counseling testing and treatment centers in Khartoum state were included. Nested PCR was done for the <em>Pol</em> gene in plasma samples that showed virologic failure, and then successfully amplified samples were sequenced for HIV-1 subtype's identification.</p> <p><strong>Result</strong>: Out of the total, 20 (18.2%) samples showed virologic failure, of them only 9 (45%) were successfully amplified and sequenced; of them, 55.6% (5/9) belonged to subtype C, and only 11.1% (1/9) occurred at the frequency of each subtype A, D, G, and K.</p> <p><strong>Conclusion</strong>: No relationship between HIV-1 subtypes and increased viral load were detected, although HIV-1 subtypes are still a strong predictor of disease progression.</p>
Evaluation of Rapid Virologic Response Among HCV Patients Treated With PegIntron and Rebetol in Brazil (Study P05427)
ClinicalTrials.gov study NCT00724854. IPD Sharing: Not stated. Countries: 0. Publications: 1.
Continuation of Protease-Inhibitor Based Second-Line Therapy vs. Switch to B/F/TAF in Virologically Suppressed Adults
ClinicalTrials.gov study NCT04311957. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Clinical, Virological, Serological and Immunological Characteristics During and Following COVID-19 Hospitalization
ClinicalTrials.gov study NCT05274373. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Gilead Sustained Virologic Response (SVR) Registry
ClinicalTrials.gov study NCT01457755. IPD Sharing: Not stated. Countries: 17. Publications: 1.
Evaluation of a Dose Reduction of Darunavir (400 mg/d) in Virologically Suppressed HIV-1 Patients
ClinicalTrials.gov study NCT02384967. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Antiretroviral Resistance Detection by Ultrasensitive Pyrosequencing of the HIV-1 Genome and Virological Response to Antiretroviral Rescue Treatment
ClinicalTrials.gov study NCT01346878. IPD Sharing: Not stated. Countries: 1. Publications: 1.
DTG/3TC Fixed Dose Formulations for the Maintenance of Virological Suppression in Children With HIV Infection Aged 2 to <15 Years Old
ClinicalTrials.gov study NCT04337450. IPD Sharing: UNDECIDED. Countries: 5. Publications: 2.
Darunavir Levels, Virological Efficacy, Proviral ADN and Resistances in Patients on Darunavir/Ritonavir Monotherapy
ClinicalTrials.gov study NCT01606722. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Randomized Trial to Optimize Virologic Suppression Rates Using a Point-of-Care Urine Monitoring Assay (ROVING PUMA)
ClinicalTrials.gov study NCT06423612. IPD Sharing: YES. Countries: 1. Publications: 6.
The DTG-SWITCH Study: Longitudinal Analysis of Virologic Failure and Drug Resistance at and After Switching to Dolutegravir-based First-line ART
ClinicalTrials.gov study NCT04612452. IPD Sharing: UNDECIDED. Countries: 2. Publications: 1.
Durability of Virologic Response and/or Viral Resistance Patterns in Participants With Chronic Hepatitis C Who Have Been Previously Treated With Grazoprevir (MK-5172) (MK-5172-017)
ClinicalTrials.gov study NCT01667081. IPD Sharing: YES. Countries: 0. Publications: 1.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.